Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
Edlin
B R
BR
Urban Health Study, Institute for Health Policy Studies, University of California, San Francisco 94110, USA. bredlin@itsa.ucsf.edu
Seal
K H
KH
Lorvick
J
J
Kral
A H
AH
Ciccarone
D H
DH
Moore
L D
LD
Lo
B
B
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004992:Ethics, Medical; D006291:Health Policy; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D018447:Medical Futility; D010349:Patient Compliance; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011287:Prejudice; D012008:Recurrence; D012306:Risk; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000628:therapy; D019966:Substance-Related Disorders / Q000150:complications / Q000628:therapy; D014481:United States / Q000453:epidemiology; D028761:Withholding Treatment
D000998:Antiviral Agents; D007372:Interferons